It’s been another whirlwind year in the world of pharma marketing. | Updates on DTC advertising and DTP programs, as well as special reports, event coverage and, of course, news bulletins from the ...
Nine large pharma companies have reached agreements with the Trump administration to lower certain drug prices in the U.S. | ...
In a merger of rare disease specialists, BioMarin has agreed to acquire Amicus Therapeutics for $4.8 billion. The California ...
In the last Fierce Pharma Asia weekly news roundup of 2025, Daiichi Sankyo scored a key FDA approval for ...
With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...
Seven years after the FDA's accelerated approval of bleeding reversal agent Andexxa, which was then under the ownership of ...
Pharma marketers enter 2026 asking where DTC fits in the DTP era. | Pharma marketers enter 2026 asking where DTC fits in the ...
Insmed has come up short in its attempt to expand its newly approved potential blockbuster Brinsupri into a new indication. | ...
As the FDA steadily churns out a stream of untitled letters chastising pharmaceutical advertisers’ direct-to-consumer ...
Medtronic initially secured FDA clearance for the MiniMed 780G pump for people with Type 1 diabetes in early 2023. This past ...
J&J has hypothesized that subcutaneous absorption of the drug may potentially enhance immune-mediated anticancer activity.
Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback